🇺🇸 FDA
Patent

US 12239717

Muscle targeting complexes and uses thereof for treating dystrophinopathies

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12239717 (Muscle targeting complexes and uses thereof for treating dystrophinopathies) held by Dyne Therapeutics, Inc. expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K38/00, A61K47/6807